Anthem Biosciences Limited

Anthem Biosciences Limited

Anthem Biosciences Limited has closed its trading window for insiders due to the upcoming board meeting to approve financial results for the quarter ending June 30, 2026.

Anthem Biosciences Limited

Ajay Bhardwaj has submitted a disclosure to the exchange under Regulations 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations primarily relate to the disclosure of shares encumbered by promoters or persons in control, and public announcements regarding the release or invocation of such encumbrances. The announcement indicates compliance with regulatory requirements.

Anthem Biosciences Limited

Anthem Biosciences Limited has received a disclosure from K Ravindra Chandrappa, a member of the promoter group, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation pertains to disclosures related to encumbered shares by promoters. However, the specific details of the disclosure, such as whether it involves the creation or release of share encumbrance, are not provided in this announcement.

Anthem Biosciences Limited

Anthem Biosciences Limited has received a disclosure from Ganesh Sambasivam regarding compliance with Regulations 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations primarily mandate disclosures related to creation, invocation, or release of encumbrances (pledges) on shares held by promoters or persons acting in concert. The announcement indicates a routine regulatory filing concerning changes in pledged share status.